Treace Medical Concepts, Inc.

As of June 30, 2026, Treace Medical Concepts, Inc. carries a market capitalization of 258.61M, placing it among publicly traded companies globally. Its enterprise value stands at 285.68M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Treace Medical Concepts, Inc.'s next confirmed earnings release is scheduled for November 6, 2026.

As of June 30, 2026, Treace Medical Concepts, Inc. has 64.98M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 1.25, and the price-to-book ratio stands at 3.82.

These figures are as of June 30, 2026. The EV/Sales ratio of 1.39 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 285.68M versus a market cap of 258.61M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Treace Medical Concepts, Inc. maintains a current ratio of 2.90, meaning it holds 2.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 107.31, indicating elevated leverage, while an interest coverage ratio of -7.79 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Treace Medical Concepts, Inc. posted a negative return on equity (ROE) of -71.99, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -30.72, reflecting losses generated across the asset base. The company generates approximately 449,495.35 in revenue per employee across its workforce of 456.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.03 indicates how many times Treace Medical Concepts, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on November 4, 2026, Treace Medical Concepts, Inc.'s stock has declined approximately 30.98% over the past 52 weeks. The 50-day moving average sits at 4.42, while the 200-day moving average is 3.26.

Over the twelve months ended June 30, 2026, Treace Medical Concepts, Inc. generated 205.31M in revenue and converted that into -59.52M in net income, yielding earnings per share of -0.93. EBITDA reached -45.35M, while operating income came in at -53.72M.

As of June 30, 2026, Treace Medical Concepts, Inc. holds 45.62M in cash and equivalents against 72.69M in total debt, resulting in a net debt position of 46.60M. Total book value stands at 67.74M, with working capital of 78.96M providing operational flexibility.

Treace Medical Concepts, Inc. produced -14.58M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -10.47M in capital expenditures, free cash flow totaled -25.05M - equivalent to -0.39 per share.

Over the twelve months ended June 30, 2026, Treace Medical Concepts, Inc. posted a gross margin of 79.45, reflecting its pricing power and cost economics. The operating margin of -26.17 and net profit margin of -28.99 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -9.79: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -0.57, meaning Treace Medical Concepts, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Treace Medical Concepts, Inc. has an Altman Z-Score of -0.32, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.